Phospholipase Cε (PLCε) is a multifunctional enzyme implicated in cardiovascular, pancreatic, and inflammatory functions. Here we show that conditional deletion of PLCε in mouse cardiac myocytes protects from stress-induced pathological hypertrophy. PLCε small interfering RNA (siRNA) in ventricular myocytes decreases endothelin-1 (ET-1)-dependent elevation of nuclear calcium and activation of nuclear protein kinase D (PKD). PLCε scaffolded to muscle-specific A kinase-anchoring protein (mAKAP), along with PKCε and PKD, localizes these components at or near the nuclear envelope, and this complex is required for nuclear PKD activation. Phosphatidylinositol 4-phosphate (PI4P) is identified as a perinuclear substrate in the Golgi apparatus for mAKAPscaffolded PLCε. We conclude that perinuclear PLCε, scaffolded to mAKAP in cardiac myocytes, responds to hypertrophic stimuli to generate diacylglycerol (DAG) from PI4P in the Golgi apparatus, in close proximity to the nuclear envelope, to regulate activation of nuclear PKD and hypertrophic signaling pathways.
INTRODUCTION
Heart failure is a major global health problem and a leading cause of mortality. In response to high blood pressure or other cardiac stress, the adult heart remodels and enlarges in what is thought to be an initial compensatory mechanism but that is maladaptive in the long term and leads to cardiac decompensation and heart failure. One major feature of cardiac remodeling is hypertrophic growth of cardiac myocytes, driven in part by increased levels of neurohumoral agonists such as norepinephrine and endothelin-1 (ET-1), acting on G protein-coupled receptors (GPCRs) in cardiac myocytes (Rockman et al., 2002) .
Many hypertrophic agonists couple to activation of phosphoinositide-specific phospholipase C (PLC) to stimulate phosphatidylinositol 4,5-bisphosphate (PIP 2 ) hydrolysis and produce inositol 1,4,5 trisphosphate (IP 3 ) and diacylglycerol (DAG), a key reaction involved in mediating cardiomyocyte hypertrophy. Ga q , a GTP-binding protein that directly activates PLC, is a major participant in the hypertrophic process in mice (D'Angelo et al., 1997; Dorn and Brown, 1999) , and a splice variant of PLCb, PLCb1b, is required for cardiomyocyte hypertrophy in vitro driven by a-adrenergic receptor activation (Filtz et al., 2009; Grubb et al., 2011) .
A novel isoform of PLC, phospholipase Cε (PLCε), is downstream of both GPCRs and receptor tyrosine kinases by virtue of its ability to be regulated by small GTPases, including Ras, Rho, and Rap, and by heterotrimeric G protein bg subunits (Kelley et al., 2001; Smrcka et al., 2012) . We recently demonstrated that hypertrophy of neonatal rat ventricular myocytes (NRVMs) driven by ET-1, norepinephrine, or isoproterenol (Iso) was inhibited by small interfering RNA (siRNA)-mediated knockdown of PLCε (Zhang et al., 2011) . Furthermore, it was shown that PLCε scaffolds to muscle-specific A kinase-anchoring protein (mAKAP) at the nuclear envelope (NE), and disruption of this scaffolding interaction prevents development of agonist-induced hypertrophy (Zhang et al., 2011) . This suggests that PLCε generates second messengers at the NE that are required for hypertrophy.
Canonical GPCR-mediated PIP 2 hydrolysis by PLC occurs at the plasma membrane (PM), where PIP 2 is preferentially enriched. PIP 2 is not readily detectable in intracellular organelle membranes, and PI-dependent signaling processes in intracellular membranes have not been well characterized. A phosphoinositide cycle involving PIP 2 hydrolysis is present in the nuclear matrix (Divecha et al., 1993; Keune et al., 2011; Ramazzotti et al., 2011) . Turnover of nuclear PIP 2 is not subject to regulation by GPCRs, despite the presence of PLCb in the nucleus of some cells, but IGF-1 has been shown to stimulate nuclear PIP 2 hydrolysis (Cocco et al., 1989; Divecha et al., 1991) . Surprisingly, nuclear PIP 2 is not associated with NE membranes but rather is in a poorly defined detergent-resistant structure in the matrix (Keune et al., 2011) . With no apparent PIP 2 substrate at the NE, a role for a PLC-hydrolytic activity associated with the NE is not obvious, although it is theoretically possible that an NE-scaffolded PLC could gain access to nuclear PIP 2 . Phosphatidylinositol 4-phosphate (PI4P) is an alternate substrate for purified PLC in vitro that is found in intracellular membranes, but PI4P has not been shown to be a native physiological substrate for PLC in cells. PI4P has been thought of primarily as a precursor for replenishment of PI4,5P 2 during active receptor-stimulated PIP 2 hydrolysis, but recent studies indicate that PI4P itself plays other important roles in cell function (Hammond et al., 2012) .
One of the key signaling events that leads to expression of hypertrophic genes is phosphorylation of histone deacetylase (HDAC5) and subsequent binding of phosphorylated HDAC to 14-3-3 proteins in the cytoplasm (Frey and Olson, 2003) . Two key kinases that phosphorylate HDAC at the nucleus are calcium calmodulin-dependent protein kinase II (CamKII) and protein kinase D (PKD) (Frey and Olson, 2003; McKinsey, 2007) . CamKII is regulated by calcium, and PKD is regulated by DAG and phosphorylation by protein kinase C (PKC) (Rozengurt, 2011; Steinberg, 2012) , suggesting that Ca 2+ and DAG levels need to be elevated locally at the nucleus to maintain their activities. How plasma-membrane GPCR-generated signals regulate these nuclear proteins has not been carefully examined. It has been generally assumed that IP 3 generated as a result of PM PLCb activiation can diffuse through the cytoplasm to NE, where IP 3 receptors are enriched in cardiac myocytes to release a local pool of Ca 2+ (Higazi et al., 2009; Wu et al., 2006) . DAG, on the other hand, is diffusible within membranes but not between membranes, so how PKD is activated at the nucleus is unclear. There is evidence that PKD can be activated at the PM and subsequently diffuse to the nucleus (Bossuyt et al., 2011) , but whether PM signals are sufficient for this process has not been examined.
To determine the mechanistic role of PLCε in cardiac function and failure, we deleted PLCε specifically in cardiac myocytes in mice after development and examined the subcellular scaffolded signals generated in cardiac myocytes by PLCε. We show that mice with cardiac myocyte-specific deletion of PLCε are protected from pressure-overload-induced hypertrophy, clearly identifying a gene critical for the development of heart failure. Further, we define a role of nuclear-scaffolded PLCε in regulating signaling proteins that drive hypertrophy. Notably, we identify PI4P in the perinuclear Golgi apparatus as the key substrate for PLCε at the NE for generation of local DAG and subsequent nuclear PKD activation.
RESULTS

Cardiac-Specific Deletion of PLCε in PLCε
flox/flox a-MHC-MerCreMer Mice Our recent results in NRVMs show that siRNA-based depletion of PLCε prevents agonist-induced hypertrophy (Zhang et al., 2011) . This contrasts with our previous work demonstrating that global knockout of PLCε exacerbates hypertrophy in response to isoproterenol infusion (Wang et al., 2005) . To clarify the role of PLCε in cardiac function and failure, we deleted PLCε specifically in cardiac myocytes in mice after development ( Figure 1A and Figure 1A ) (Sohal et al., 2001 Figure 1E ). Previous data from global PLCε À/À mice showed no changes in levels of other PLCb1, PLCb3, PLCg1, or PLCd3 compared to PLCε +/+ mice (Wang et al., 2005) .
Cardiac-Specific Deletion of PLCε Inhibits Development of Hypertrophy after Transverse Aortic Constriction
After 4 weeks of transverse aortic constriction (TAC), PLCε flox/flox Cre À mice had increased heart size, LV and right ventricular (RV) wall thickness, and interstitial fibrosis ( Figure 1D , cre À ).
These morphological changes were significantly inhibited in the PLCε flox/flox Cre + animals ( Figure 1D , cre + ). PLCε flox/flox Cre À mice developed a severe decrement in heart function with a drastic decrease in ejection fraction and fractional shortening, had a significant increase in heart weight (HW) to tibia length (TL), and showed large increases in hypertrophic gene expression ( Figure 1E and Figures S1A and S1B available online). In contrast, PLCε flox/flox Cre + mice were significantly protected from these hypertrophy-related changes (Figures 1E, S1A, and S1B). These data indicate that cardiomyocyte PLCε plays a role in mediating cardiac hypertrophy, supporting the mechanistic data obtained in NRVMs.
Characterization of Signaling Pathways Associated with PLCε Deletion in Cardiomyocytes
In the global PLCε knockout (KO) animal, CamKII phosphorylation was basally increased (see Figure S5 in Zhang et al., 2011) , but here in the cardiac-specific KO, there was no detectable increase in CamKII phosphorylation nor PKD phosphorylation under basal conditions ( Figures 1F and S1C Figures 1F and S1C ).
Based on these data, we hypothesize that PLCε may be involved in regulation of PKD-and CAMKII-dependent phosphorylation of HDAC in cardiac myocytes.
Ga q -Dependent Hypertrophy Requires mAKAP-Bound PLCε Ga q signaling has been shown to be a primary driver of hypertrophy both in NRVMs and in mice (D'Angelo et al., 1997; Knowlton et al., 1993) . To directly test the involvement of PLCε in Ga qdependent hypertrophy, adenovirus expressing Ga q was used to infect NRVMs along with an adenovirus expressing either PLCε siRNA or a random siRNA Ctl sequence. As previously reported, expression of Ga q caused an increase in NRVM cell area (Figure 2A) and atrial natriuretic factor (ANF) mRNA ( Figure 2B ) expression, relative to infection with Ctl lacZ-or yellow fluorescent Figure S1 .
protein (YFP)-expressing viruses. Depletion of PLCε by siRNA completely inhibited the development of hypertrophy by Ga q assessed by both of these measures (Figures 2A and 2B ).
To test whether mAKAP-PLCε scaffolding was important for Ga q -dependent hypertrophy, we coexpressed Ga q with the mAKAPspectrin repeat homology domain 1 (SR1) domain, documented previously to disrupt mAKAP-PLCε interactions at the NE (Zhang et al., 2011) . Expression of the SR-1 domain almost completely inhibited hypertrophy driven by Ga q ( Figure 2C ), indicating that NE scaffolding of PLCε via mAKAP is important for Ga q -dependent NRVM hypertrophy.
Scaffolding of PLCε, PKCε, and PKD to mAKAP mAKAP is a large scaffolding protein localized to the NE in cardiac myocytes, and it scaffolds to many partners, including PLCε (Dodge-Kafka et al., 2005; Kapiloff et al., 2001; Zhang et al., 2011) . We have shown by biochemical fractionation that PLCε is localized to the nuclear fraction of cardiac myocyte lysates along with mAKAP (Zhang et al., 2011) . Expression of PLCε fused to mCherry was enriched at the periphery of the nucleus in NRVMs ( Figure 3A) , and some PLCε is localized to endoplasmic reticulum/ sarcoplasmic reticulum (ER/SR)-like structures.
To identify other components in this complex that are potentially involved in PLCε signaling, we immunoprecipitated PLCε from mouse heart lysates and immunoblotted for key potential upstream regulators and downstream targets. First we looked for Epac1 association because Epac is upstream of PLCε-dependent regulation of cardiac contractile function and has been previously identified in mAKAP immunoprecipitates (Dodge-Kafka et al., 2005; Oestreich et al., 2007 Oestreich et al., , 2009 ). Both PLCε and mAKAP immunoprecipitates contained Epac1 (Figure 3B) . When PLCε was cotransfected into HEK293 cells with Epac1, Epac1 was detected in PLCε immunoprecipitates (Figure S2A) . Coexpression of mAKAP did not alter the efficiency of the immunoprecipitation, suggesting that PLCε directly binds to Epac1. To further characterize the interaction, purified GSTEpac1 was tested for binding to purified PLCε. GST-Epac1 specifically bound to PLCε, confirming a direct interaction (Figure S2B) . To determine whether interaction of Epac1 with PLCε was required for association with AKAP in the heart, we compared AKAP immunoprecipitates from PLCε À/À and PLCε +/+ mouse heart lysates ( Figure S2C ). Epac1 was detectable in the lysates from both genotypes, but the level of Epac1 was significantly lower in immunoprecipitates from PLCε À/À mouse hearts, suggesting that binding of Epac1 to PLCε contributes to scaffolding of Epac1 to mAKAP. We had also previously shown that PLCε regulates phosphorylation of Ryr2 through a PKCε-and CamKII-dependent mechanism during acute b-adrenergic receptor (bAR) activation (Oestreich et al., 2009 ). We examined PLCε immunoprecipitates (C) NRVMs were cotransduced with adenoviruses expressing Ga q and mAKAP-SR domain. ANF/ GAPDH ratio was measured after 48 hr (± SEM). All experiments were repeated three times and were analyzed by one-way ANOVA, *p < 0.05; ***p < 0.005.
for the presence of Ryr2 and found Ryr2 immunoreactivity only in lysates from hearts isolated from PLCε +/+ mice (Figure 3C) . Ryr2 has been shown to bind to mAKAP, so it is possible that this interaction is indirect. When coexpressed in HEK293 cells, Ryr2 weakly interacted with PLCε in a manner that was not affected by coexpression of mAKAP (data not shown). This suggests that mAKAP does not mediate Ryr2 scaffolding to PLCε, but because the PLCε-Ryr2 interaction is weaker in cotransfected cells than in heart lysates, another protein is likely to participate in PLCε-Ryr2 scaffolding. Immunodepletion of heart lysates with mAKAP antiserum reduces, but does not eliminate, Ryr2 immunoprecipitation with PLCε (Figure S2D ). This indicates that a fraction of PLCε is scaffolded to Ryr2 but is not associated with mAKAP, supporting the existence of multiple pools of PLCε in cardiac myocytes.
Because PKCε and PKD are critical hypertrophic kinases that we propose are downstream of PLCε, we examined their scaffolding to mAKAP and PLCε. We had previously shown that PLCε mediates PKCε activation in adult cardiac myocytes during acute bAR stimulation (Oestreich et al., 2009 ). PLCε and mAKAP immunoprecipitates from heart lysates contained both PKCε and PKD immunoreactivity ( Figures 3D and 3E ). PLCε immunoprecipitates from hearts isolated from PLCε À/À mice did not contain PKCε immunoreactivity confirming the specificity of the immunoprecipitation. Together, these data indicate that many of the signaling components required for PLCε action in cardiac myocytes involved in either regulation of contraction or hypertrophy are assembled into a signaling complex with mAKAP. More importantly, these data show that the key hypertrophic regulators, PKCε and PKD, are scaffolded with PLCε and mAKAP at the NE, where they play key functional roles analyzed below.
mAKAP-Bound PLCε Is Involved in Nuclear PKD Activation in NRVMs
To test the involvement of PLCε in ET-1-dependent PKD activation, PLCε was depleted in NRVMs using siRNA, and PKD S916 phosphorylation was measured. PKD phosphorylation increases after 10 min of ET-1 stimulation and declines thereafter but remains active for at least 4 hr ( Figure S3 ). ET-1 stimulation of PKD phosphorylation in PLCε siRNA-treated NRVMs was blunted compared to Ctl siRNA-treated cells at all times measured. We more carefully examined inhibition by PLCε depletion after stimulation with ET-1 and norepinephrine for 1 hr and ET-1 for 24 hr ( Figure 4A ). At both times, ET-1-dependent PKD phosphorylation was inhibited in PLCε siRNA-treated NRVMs by approximately 50%. This indicates that PLCε is important for activation of PKD, but because inhibition of total cellular PKD activation by PLCε depletion is partial, PLCε may be regulating a specific subcellular pool of PKD.
To determine whether mAKAP-associated PLCε was involved in PKD activation, PLCε-mAKAP interactions were disrupted by expression of mAKAP-SR1 or PLCε-ras-association 1 (RA1) domains (Zhang et al., 2011) , and ET-1-stimulated phosphorylation of PKD at 1 hr and 24 hr was measured. Expression of either PLCε-RA1 or mAKAP-SR1 domains inhibited ET-1-dependent global PKD phosphorylation at 1 hr (30%) and 24 hr (70%) (Figure 4B) . To determine whether PLCε is required for activation of the nuclear pool of PKD, NRVMs were transduced with an adenovirus expressing a nuclear-targeted fluorescence resonance energy transfer (FRET)-based reporter of PKD activity, nuclear D kinase activity reporter (nDKAR) (Bossuyt et al., 2011; Kunkel et al., 2007) . Figure 4C is a YFP/ cyan fluorescent protein (CFP) ratiometric image from NRVMs expressing nDKAR, with CFP excitation showing basal FRET in the nucleus as previously reported (Bossuyt et al., 2011) . NRVMs were treated with either vehicle or ET-1, and nuclear FRET was monitored over time. ET-1 treatment causes a significant decrease in nuclear FRET over the course of 20 min compared to vehicle Ctl ( Figures  4D and 4E) . In NRVMs treated with PLCε siRNA, the ET-1-induced decrease in FRET was completely eliminated ( Figures  4D and 4E) . Expression of mAKAP-SR1 in NRVMs also completely inhibited the ET-1-dependent decrease in nDKAR FRET ( Figure 4F ). This indicates that ET-1 activates nuclear PKD, and that this nuclear PKD activation requires mAKAP-scaffolded perinuclear PLCε.
PLCε Is Important for Localized Nuclear Calcium Signals ET-1 induces calcium increases in the nuclei of cardiac ventricular myocytes; this process is dependent on IP 3 presumably binding to type II IP 3 receptors localized at the NE (Higazi et al., 2009; Wu et al., 2006) . Several reports indicate that the myocyte nuclear Ca 2+ release via IP 3 receptors can mediate cardiomyocyte hypertrophy (Arantes et al., 2012; Higazi et al., 2009; Nakayama et al., 2010) . To monitor changes in nuclear calcium levels, we utilized Fura-2-loaded NRVMs and specifically monitored the nuclear regions of the cells by ratio imaging epifluorescence microscopy ( Figure 5A ). NRVMs were pretreated with nifedipine (L-type Ca 2+ channel blocker) and mibefradil (L-and T-type Ca 2+ channel blocker) to block Ca 2+ entry and Ca
2+
release associated with myocyte excitation contraction (Higazi et al., 2009 ). ET-1 stimulated an increase in nuclear [Ca 2+ ] that was inhibited by PLCε siRNA treatment ( Figure 5A) . Expression of the RA domain of PLCε to disrupt AKAP-dependent nuclear scaffolding also inhibited nuclear Ca 2+ release but only by 10%-20% ( Figure 5A , middle right panel). This nuclear Ca 2+ release is likely IP 3 dependent, as previously reported (Higazi et al., 2009) , because it was not affected by blocking the other major Ca 2+ -release channel, Ryr2, with ryanodine ( Figure 5A , right panel). To confirm that the ET-1-dependent Ca 2+ increases are localized to the nucleus, we used two-photon microscopy to examine ET-1-dependent increases in nuclear Ca 2+ signals in NRVMs. Treatment with ET-1 results in a robust Ca 2+ release that is primarily restricted to the nucleus ( Figure 5B ; Movie S1), as previously reported. These data indicate that IP 3 generated by PLCε-dependent PIP 2 hydrolysis contributes to nuclear Ca 2+ signals that may be important for regulation of hypertrophy, but that PLCε scaffolded at the NE is not a major participant in this release. This suggests that PLCε localized elsewhere, possibly at the PM, contributes to diffusible IP 3 generation necessary for release of Ca 2+ at the NE.
Perinuclear PI4P Localization
To identify potential perinuclear substrates for PLCε, we utilized specific fluorescent probes containing GFP fused to domains that recognize specific phosphoinositides (Balla et al., 2009 ).
PLCε PLC ε Ryr2
No Ab PLC ε Ryr2 To localize PIP 2 , we transfected cells with reporters containing GFP fused to the pleckstrin homology (PH) domain of PLCd or the PIP 2 -binding domain of Tubby and examined the cells by confocal fluorescence microscopy. Both of these constructs bind to PIP 2 specifically, but PLCd-PH also binds IP 3 . Transfection of GFP-Tubby ( Figure 6A ) or GFP-PLCd-PH (not shown) into HEK293 cells revealed a prominent PM distribution of PIP 2 with some intracellular fluorescence but no obvious localization near the NE ( Figure 6A ). Transfection of NRVMs with the same constructs revealed a similar PM distribution of PIP 2 ( Figure 6A ). Thus PIP 2 is not detectable at the NE in NRVMs and is likely not available as a substrate for NE-scaffolded PLCε activity. PI4P is also a substrate for PLCε and other mammalian PLC isoforms in vitro, but its utilization as a substrate in cells has not been demonstrated (Rhee et al., 1989; Seifert et al., 2004; Smrcka et al., 1991) . To determine the localization of PI4P in NRVMs, cells were transfected with reporters containing GFP fused to the PH domains of either four-phosphate adaptor protein (FAPP) or oxysterol-binding protein (OSBP). These reporters selectively monitor PI4P subcellular localization in living cells, but this binding is codependent on interaction with the small GTPase ARF (Balla et al., 2005) . Thus they readily detect PI4P at intracellular membranes containing ARF. As previously reported in other cultured cells, transfection of GFP-FAPP-PH into HEK293 cells leads to prominent fluorescence at asymmetrically localized structures that correspond to the Golgi apparatus ( Figure 6B, left panel) . Surprisingly, and in striking contrast to other cultured cells, both FAPP-PH-GFP and OSBP-PH-GFP strongly show a ring of perinuclear fluorescence surrounding the nucleus in NRVMs ( Figure 6B , middle and right panels and Figure S4A) . In some cells, other intracellular structures resembling either Golgi or SR were labeled (Figure 6C , for example), but this was generally less prominent. Treatment with Brefeldin A to inhibit ARF resulted in rapid depletion of perinuclear FAPP-PH-GFP fluorescence ( Figure 6C ). Perinuclear FAPP-PH-GFP fluorescence was also completely disrupted by treatment with PI4-kinase inhibitor phenylarsine oxide (PAO) ( Figure 6D ).
Brefeldin A is an agent used to disrupt the Golgi apparatus through its ability to block Golgi-localized ARF. ARF and PI4P are enriched in the Golgi in most cells and play important roles in Golgi-membrane vesicle and lipid trafficking. This suggested that the perinuclear PI4P may be in Golgi closely associated with the outer surface of the nucleus. reporters ( Figure S4B ). Indeed, previous studies have shown that the Golgi surrounds the nucleus in myocytes and is intimately associated with the NE at a constant distance of 100-200 nm (Kronebusch and Singer, 1987; Tassin et al., 1985) . Together these data indicate that PI4P is localized to the Golgi apparatus, in close proximity to the NE, where it could be accessed by mAKAP-scaffolded PLCε.
PLCε Activation at the NE Leads to PI4P Depletion and DAG Generation To assess whether perinuclear PI4P is a substrate for PLCε, we treated cells with a specific activator of Epac, 8-(4-chlorophenylthio)-2 0 -O-methyl-cAMP (cpTOME). Epac-dependent Rap activation stimulates PLCε but no other PLC isoforms, and Epac is scaffolded at the NE with PLCε and mAKAP. Thus, PLCε in this NE-signaling complex can be activated selectively with cpTOME. Treatment of NRVMs with cpTOME for 1 hr caused a significant depletion of perinuclear Golgi FAPP-PH-GFP fluorescence ( Figure 7A ). Selected regions of perinuclear FAPP fluorescence were monitored in single live cells over time after addition of vehicle Ctl, cpTOME, or ET-1 ( Figure 7B ; Movie S2). Both cpTOME and ET-1 treatment enhanced the rate of depletion of FAPP-PH-GFP fluorescence compared to vehicle Ctl. ET-1-dependent decreases in PI4P were blocked by preincubation with the ET-1a receptor antagonist BQ-123 ( Figure 7B ). We used a PI4P strip mass assay to measure total PI4P levels in NRVMs after vehicle or cpTOME treatment (Dowler et al., 2002) . Treatment with cpTOME led to a significant decrease in cellular PI4P mass compared to vehicle-treated NRVMs ( Figure 7C ). Similar studies examining PIP 2 at the PM indicate that cpTOME does not stimulate PM-dependent PIP 2 depletion ( Figure S5A ). To show that ET-1-dependent perinuclear PI4P depletion was dependent on mAKAP-scaffolded PLCε, cells were cotransfected with GFP-FAPP-PH and either mAKAP-SR1 or Ctl vector ( Figure 7D ). In cells transfected with mAKAP-SR1, ET-1-dependent depletion of PI4P was blocked. Additionally, as shown in Figure 7E , depletion of PLCε with PLCε-siRNA completely eliminated cpTOME-dependent depletion of perinuclear PI4P. These data strongly indicate that mAKAP-scaffolded PLCε is directly involved in perinuclear PI4P depletion consistent with its activity as a perinuclear enzyme that can hydrolyze PI4P ( Figure S5B ) to produce DAG.
One consideration is that although PIP 2 is undetectable in the perinuclear Golgi in cardiac myocytes ( Figure 6A ), there could be a very low level of PIP 2 that is the direct substrate for perinuclear PLCε. In this scenario, PI4P might be indirectly depleted to replace the hydrolyzed PIP 2 pool. To test this, a PI5 phosphatase was targeted to the Golgi or the PM with a rapamycinrecruitable type IV PI5P ptase domain fused to FKBP12 (Varnai et al., 2006) . This PI5 ptase cleaves the 5-phosphate from PI4,5P 2 , effectively depleting PIP 2 . Figure S6A shows that targeting of the PI5 ptase to the PM eliminates GFP-Tubby labeling of the PM, indicating that the targeted PI5 ptase depletes PM PIP 2 . Targeting of the PI5 ptase to the Golgi with rapamycin does not alter PI4P levels ( Figures S6B and S6C , black squares). Treatment with cpTOME depletes PI4P at the perinuclear Golgi at the same rate in the presence or absence of rapamycin-dependent targeting of the PI5P ptase to the Golgi All experiments were repeated a minimum of three times. See also Figure S4 .
( Figure S6C ). This indicates that perinuclear Golgi PI4P depletion is not dependent on PIP 2 hydrolysis in the Golgi, further supporting the idea that the direct substrate for perinuclear PLCε is PI4P.
To test for production of perinuclear DAG, cells were transfected with a DAG-binding domain (C1b domain of PKCbII with a Y123W mutation) that is fused to YFP (YFP-C1b-Y123W), binds with high affinity to DAG, and translocates to membranes where DAG is produced (Kunkel and Newton, 2010) . In resting cells, there was basal association of the reporter with perinuclear and other cellular membranes ( Figure 7F ). This could be due to basal turnover of lipids in the Golgi in the presence of serum, or the very high affinity of this reporter for DAG could stabilize a turning-over DAG pool. Nevertheless, treatment with cpTOME increased the association of a DAG reporter with the perinuclear region of the cell. The increase was small ($10% increase) but reproducible and consistent with what has been previously observed for this DAG reporter in the Golgi in other cell types (Kunkel and Newton, 2010) . Thus DAG is generated in close proximity to the NE by stimulation of PLCε. Before cpTOME cpTOME (1 hr) (A) NRVMs transfected with FAPP-PH-GFP were analyzed by live-cell confocal microscopy before and after treatment with 10 mM cpTOME for 1 hr (see also Movie S2). (B) Individual regions of GFP fluorescence in NRVMs transfected with FAPP-PH-GFP were monitored with confocal microscopy and followed with time after treatment with vehicle, 10 mM cpTOME, 50 nM ET-1, or 50 nM ET-1+ 100 nM BQ-123 (top panels are representative traces). Data were pooled from four experiments at 0 and 50 min for quantitation and statistics (bottom panels). (C) NRVMs were treated with vehicle or 10 mM cpTOME for 50 min followed by extraction of PI4P and assay using a PI4P protein-lipid overlay assay according to the manufacturer's instructions. Data from three separate experiments are quantitated in the bottom panel and analyzed by a Student's t test. (D) NRVMs were cotransfected with FAPP-PH-GFP and either mAKAP-SR1 or control plasmid. Perinuclear GFP fluorescence was monitored as in (B). ET-1 experiments in (B) and (D) were done in parallel so the ET-1 alone representative traces are the same in both panels. Top panel is a representative trace, and bottom panel is pooled data from three experiments analyzed by one-way ANOVA. (E) NRVMs were transfected with FAPP-PH-GFP and transduced with viruses expressing PLCε siRNA or random control siRNA, and perinuclear GFP fluorescence was monitored as in (B) and (D). Data are pooled from five independent experiments each. (F) NRVMs were transfected with YFP-C1b-Y123W to detect DAG localization. Left panel shows localization of YFP-C1b-Y123W by confocal microscopy. Right panel: NRVMs transfected with YFP-C1b-Y123W were stimulated with 10 mM cpTOME, and perinuclear regions and cytoplasm were imaged over time. The ratio of perinuclear fluorescence (F pn ) to the cytoplasmic fluorescence (F c ) was calculated and normalized to the starting F pn /F c before cpTOME addition. Data are pooled from four independent experiments; F pn /F c at 9-12 min were individually compared with F pn /F c at 0 min with a one-way ANOVA. (G) Golgi-specific depletion of PI4P blocks ET-1-dependent nuclear PKD activation. Left panel: Cells were transduced with GFP-tagged, Golgi-targeted Sac-1 and imaged by confocal microscopy. Right panel: Cells were cotransfected with plasmids expressing nDKAR and Golgi-targeted Flag-tagged Sac-1 plasmids, and nDKAR FRET was monitored as in Figures 4D and 4F . Fifty nanomolar ET-1 was added at the indicated time. Data were pooled from four independent cells for each treatment from two separate NRVM preparations. All data are ± SEM. See also Figures S5, S6 , and S7 and Movie S2.
To test whether PI4P is required for nuclear PKD activation, PI4P was depleted in NRVMs using PAO (as shown in Figure 6D ), and ET-1-dependent nuclear PKD activity was monitored using nDKAR ( Figure S7 ). PAO depletes cellular PI4P in cells without depleting the PIP 2 pools necessary for conventional PLC-mediated PIP 2 hydrolysis (Hammond et al., 2012) . By examining the effect of PAO treatment on GFP-Tubby fluorescence, we also found that PAO does not deplete NRVM PIP 2 (data not shown). PAO treatment completely eliminated ET-1-dependent nuclear PKD activation, indicating that PI4P is a required substrate for nuclear PKD activation, which supports the idea that Golgi PI4P is required for nuclear PKD activation.
To more directly show that Golgi-localized PI4P is required for nuclear PKD activation, we transfected cells with a variant of the PI4P-specific phosphatase, Sac1, with a mutation leading to specific localization in the Golgi (Sac1-K2A) (Blagoveshchenskaya et al., 2008; Rohde et al., 2003) . In the left panel of Figure 7G is an NRVM transfected with GFP-Sac1-K2a, showing perinuclear Golgi localization of Sac1-K2A. Sac1-K2A transfection completely eliminated the ET-1-dependent decrease in nDKAR FRET, demonstrating that PI4P in the Golgi is required for nuclear PKD activation ( Figure 7G, right panel) . We conclude that mAKAP-scaffolded PLCε generates DAG from PI4P in close proximity to the NE required for nuclear PKD activation.
DISCUSSION
We previously demonstrated that PLCε integrates multiple hypertrophic stimuli in neonatal rat ventricular myocytes (Zhang et al., 2011 ). Here we demonstrate that cardiac-specific deletion of PLCε after 1 month of development significantly inhibits cardiac hypertrophy development. This strongly suggests that PLCε signaling in the cardiac myocyte is important for hypertrophy development, and that the neonatal myocyte analysis of PLCε function is largely relevant to whole-heart function in an animal.
Our previously published data established that both phosphoinositide hydrolysis by PLCε and NE scaffolding of PLCε via mAKAP are required for PLCε-dependent hypertrophy in NRVMs (Zhang et al., 2011) . This suggested that PLCε must be generating IP 3 , DAG, or both at the NE to drive hypertrophic signaling cascades at the nucleus. IP 3 generated at the PM is diffusible, so agonist-dependent nuclear Ca 2+ release could be controlled by IP 3 generated from PM PIP 2 pools. DAG, on the other hand, is a membrane-bound lipid, not freely diffusible between membranes, and therefore must be produced in the vicinity of the nucleus to regulate nuclear signaling proteins. Here we show that PLCε is important for agonist-dependent regulation of both nuclear Ca 2+ release and PKD activation.
PLCε scaffolded at the NE is required to generate perinuclear DAG important for nuclear PKD activation, but surprisingly, the substrate for this reaction is in the uniquely localized perinuclear Golgi apparatus. PKD is recruited to the Golgi apparatus in a DAG-dependent manner in other cell types where it is involved in lipid and vesicle trafficking (Campelo and Malhotra, 2012) . PLC, PKD, and ARF are critical regulators of Golgi fission involved in the transport of cargo to the PM. Here, with the unique architecture of the Golgi apparatus in cardiac myocytes and the perinuclear scaffolding of PLCε by mAKAP, the process of PI hydrolysis and DAG generation appears to have been coopted to recruit and activate PKD in the vicinity of the nucleus, where it can regulate nuclear gene expression. Although we and others have shown that PI4P is a substrate for mammalian PLC isoforms, including PLCε, in vitro (Figure S5B ), PI4P has not been shown to be a native physiological substrate for any mammalian PLC in cells. Thus, we demonstrate here that PI4P hydrolysis is a physiologically relevant PLC reaction that likely performs a widespread function in cell biology. PI4P has generally been thought to function primarily as a precursor to replace PIP 2 as it is depleted by receptor-stimulated PIP 2 hydrolysis. Recently however, it has been shown that depletion of PI4P does not significantly alter the level of PIP 2 in cells, nor does it affect acute receptor-stimulated PIP 2 hydrolysis, indicating that PI4P has functional roles other than simply serving as a PIP 2 precursor (Hammond et al., 2012) .
We also show that PLCε is involved in regulation of ET-1-dependent nuclear Ca 2+ elevation. Previous studies have indicated that local Ca 2+ signaling at the nucleus is IP 3 receptor dependent and regulates HDAC nuclear export via activation of CamKII (Wu et al., 2006) . The source of IP 3 was undefined in these experiments but has been suggested to diffuse from the PM. Hydrolysis of PI4P by PLC activity would generate DAG and inositol 1,4-bisphosphate (IP 2 ) and thus would not be a relevant reaction for local IP 3 -dependent Ca 2+ release because IP 2 does not regulate Ca 2+ release through IP 3 receptors. Thus the role of PI4P hydrolysis by mAKAP-scaffolded PLCε at the Golgi appears to be DAG generation for PKD activation. We propose that a different pool of PLCε, perhaps at the PM in cooperation with PLCb, generates IP 3 from PIP 2 , which can diffuse to the nucleus and release Ca 2+ via IP 3 receptors in the nucleus. Overall, our model is that PLCε is located in different subcellular compartments, allowing for regulation of hypertrophy and CICR via different mechanisms.
In conclusion, we have discovered a novel integrator of hypertrophic signals in the heart, PLCε, whose scaffolding at the NE to generate DAG from the novel PLC substrate PI4P in the perinuclear Golgi apparatus is critical for this function. This suggests that PLCε catalytic activity could be a novel target for heart failure. On the other hand, PLCε is found in many cell types and has multiple functions (Smrcka et al., 2012) . Global deletion of PLCε increases the propensity for heart failure (Wang et al., 2005) . mAKAP has a more restricted distribution and thus so does the PLCε-mAKAP complex (Kapiloff et al., 1999) . A more targeted strategy for treatment of heart failure could involve developing reagents that interfere with PLCε scaffolding to mAKAP.
EXPERIMENTAL PROCEDURES
See the Extended Experimental Procedures for detailed methodology. mice were subjected to TAC or sham operation (opening and closing chest without aortic banding). Mice were anesthetized with isoflurane anesthesia (2% inhaled) and intubated. Essentially as described by ourselves and others, a transaortic constriction was produced (Ram et al., 2011; Rockman et al., 1991) .
Echocardiography
Transthoracic 2D and M-mode echocardiography analysis was used to assess heart function after 4 weeks of TAC in mice under minimal isoflorane anesthesia with similar heart rates across animals using a Visualsonics Vevo 2100 echocardiography system (Visualsonics, Toronto, ON), using methods as we have recently described (Ram et al., 2011) .
Morphological Assessment of Hypertrophy
After 6 weeks of TAC, mice were euthanized, and hearts were harvested. Heart and tibias were dissected. Heart weight and TL were measured. For histological analysis, hearts were perfused and fixed with 10% formalin.
Isolation, Culture, Adenoviral Infection, siRNA Treatment, and Hypertrophy Analysis of NRVMs Isolation of NRVMs, adenoviral-mediated siRNA of PLCε, hypertrophy induction, and analysis were as previously described (Zhang et al., 2011) .
Imaging of Phosphoinositide and DAG Reporters
Cells were imaged 24-48 hr after transfection with the appropriate plasmid at 1-2 mg. Transfection efficiency was approximately 5%. Fluorescent cells were identified and imaged by confocal microscopy. During imaging and cpTOME, ET-1, BFA, and PAO treatments, cells were in culture medium containing serum. EGFP: excitation 488 nm, emission 510 nm; YFP: excitation 515 nm, emission 527 nm; mCherry and mRFP: excitation 559 nm, emission 618 nm; CFP: excitation 440, emission 476; DAPI and Hoeschst stains: excitation 405 nm, emission 461 nm.
Ca
2+ Imaging
NRVMs were cultured on laminin (25 mg/ml; Invitrogen) coated coverslips. For epifluorescent Ca 2+ imaging, myocytes were loaded with Fura-2AM (2 mM) in imaging buffer (HBSS containing in mM: 5.5 glucose, 0.56 MgCl 2 , 4.7 KCL, 1 Na 2 HPO 4 , 10 HEPES, 1.2 CaCl 2 , pH 7.4). One hundred micromolar ryanodine was loaded in conjunction with Fura-2 dye for the ryanodine receptor block experiments. For measurement of nuclear Ca 2+ by two-photon microscopy, myocytes were loaded with Fluo-4AM (2 mM) in imaging buffer. Fluo-4: excitation 820 nm, emission 520 nm.
nDKAR FRET NRVMs were transduced with an nDKAR-expressing adenovirus. Transduced cells were identified with CFP excitation and emission. FRET was determined as the ratio of YFP emission at 535 nm to CFP emission at 480 nm after CFP excitation at 440 nm.
Measurement of PI4P Mass PI4P was extracted from either vehicle-or cpTOME-treated myocytes (1 hr) using a MeOH, CHCl 3 , HCl extraction protocol (Gray et al., 2003) . The extract was spotted onto a nitrocellulose filter, and PI4P was detected using a PI4P protein lipid overlay assay according to the manufacturer's instructions (Echelon Biosciences Inc.) (Dowler et al., 2002) .
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